HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

In Brief: P&G stock repurchase program

This article was originally published in The Rose Sheet

  • News
  • The Rose Sheet

Executive Summary

P&G stock repurchase program: Procter & Gamble board authorizes the annual repurchase of 4-5 mil. common stock shares, the firm announces March 27. "Our objective in repurchasing Procter & Gamble stock will be to eliminate any dilution of per share earnings resulting from management compensation programs," Chairman and CEO Edwin Artzt explained. The program, effective March 31, should "enhance shareholder value without restricting our ability to invest in the company's future growth," Artzt added...

Table

View full table

Tags:
Latest Headlines

Need Advice About Advisory Committees, US FDA? Try Having Some

FDA Advisory Committee Reform: Does Listening Session Suggest No Major Near-Term Changes?

People On The Move: Appointments At Haleon, Bayer, Abdi Ibrahim

AI News: Lauder Expands Microsoft Partnership; Prose Beauty; Supply Chain Software; More

See All
UsernamePublicRestriction

Register

RS001476

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By